Aberrations in oncogenic pathways and immune modulation influence treatment response in patients with metastatic leiomyosarcoma or liposarcoma.
The statistical significance of the improvements varied depending on how progression-free survival was measured.
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, of Duke...
From the Journals
Overall survival with eribulin was 15.6 versus 8.4 months with dacarbazine in a phase 3 randomized trial of 452 patients with advanced liposarcoma...